Radiopharm Theranostics Limited Sponsored ADR (RADX)
NASDAQ:RADX
RADX Stock Chart & Stats
$4.14
-$0.80(-17.20%)
At close: 4:00 PM EST
$4.14
-$0.80(-17.20%)
Day’s Range― - ―
52-Week Range$3.50 - $16.25
Previous CloseN/A
Volume12.21K
Average Volume (3M)40.07K
Market Cap
$47.01M
Enterprise Value$19.79M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Sep 24, 2026EPS Estimate
-1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.11
Shares Outstanding11,814,054
10 Day Avg. Volume24,103
30 Day Avg. Volume40,070
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.09
Price to Sales (P/S)13.46
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$30.00Price Target Upside624.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.86
Revenue Forecast (FY)$1.28M
Bulls Say, Bears Say
Bulls Say
Clinical Utility In Brain MetastasesRAD101 demonstrated the ability to distinguish necrotic tissue from active tumor after stereotactic radiosurgery, which could improve diagnostic accuracy and better inform treatment decisions for patients with brain metastases.
Diagnostic Performance Of RAD101Interim imaging showed strong concordance between RAD101 PET and MRI, and early pancreatic imaging detected very small primary and metastatic lesions, indicating promising sensitivity for difficult-to-detect disease.
Platform Growth And Non-dilutive Funding PotentialThe company's combined imaging and therapeutic radiopharmaceutical portfolio creates opportunities for medium- to long-term growth and could attract partnerships that provide non-dilutive capital to support development.
Bears Say
Cash Runway And Financing RiskLimited cash resources could constrain ongoing development programs unless additional partnerships or financing are secured, increasing the risk of program slowdowns or dilution.
Risk Of Underperformance In Pivotal TrialsCurrent indications of tumor uptake and imaging concordance may not translate into the sensitivity and specificity required in a pivotal trial, creating execution risk for regulatory approval pathways.
Uncertain Validation For Newer Molecular TargetsA gap between clinical results for established targets and outcomes for newer molecular targets raises uncertainty about whether the company's less-validated targets will achieve comparable clinical performance.
Radiopharm Theranostics Limited Sponsored ADR News
RADX FAQ
What was Radiopharm Theranostics Limited Sponsored ADR’s price range in the past 12 months?
Radiopharm Theranostics Limited Sponsored ADR lowest stock price was $3.50 and its highest was $16.25 in the past 12 months.
What is Radiopharm Theranostics Limited Sponsored ADR’s market cap?
Radiopharm Theranostics Limited Sponsored ADR’s market cap is $47.01M.
When is Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date?
Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date is Sep 24, 2026 which is in 182 days.
How were Radiopharm Theranostics Limited Sponsored ADR’s earnings last quarter?
Radiopharm Theranostics Limited Sponsored ADR released its earnings results on Feb 27, 2026. The company reported -$2.106 earnings per share for the quarter, missing the consensus estimate of -$2.096 by -$0.01.
Is Radiopharm Theranostics Limited Sponsored ADR overvalued?
According to Wall Street analysts Radiopharm Theranostics Limited Sponsored ADR’s price is currently Undervalued.
Does Radiopharm Theranostics Limited Sponsored ADR pay dividends?
Radiopharm Theranostics Limited Sponsored ADR does not currently pay dividends.
What is Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate?
Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate is -1.42.
How many shares outstanding does Radiopharm Theranostics Limited Sponsored ADR have?
Radiopharm Theranostics Limited Sponsored ADR has 11,814,054 shares outstanding.
What happened to Radiopharm Theranostics Limited Sponsored ADR’s price movement after its last earnings report?
Radiopharm Theranostics Limited Sponsored ADR reported an EPS of -$2.106 in its last earnings report, missing expectations of -$2.096. Following the earnings report the stock price went up 0.201%.
Which hedge fund is a major shareholder of Radiopharm Theranostics Limited Sponsored ADR?
Currently, no hedge funds are holding shares in RADX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Radiopharm Theranostics Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (624.64% Upside)
$30.00 (624.64% Upside)
Blogger Sentiment
Neutral
RADX Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.62%
12-Months-Change
Fundamentals
Return on Equity
0.00%
Trailing 12-Months
Asset Growth
6.21%
Trailing 12-Months
Company Description
Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
RADX Stock 12 Month Forecast
Average Price Target
$30.00
▲(624.64% Upside)
Technical Analysis
Serina Therapeutics
―
Celularity
―
Barinthus Biotherapeutics
―
Acrivon Therapeutics, Inc.
―
Telomir Pharmaceuticals, Inc.
―